



Every 60 seconds at Priceline Pharmacy there are*:

- 29 makeup products sold
- 12 haircare products sold
- 8 vitamin & supplement products sold
- 4 fragrance products sold
- 3 lash products sold
- 2^ vaccinations administered
- 56^ scripts dispensed

When you partner with Priceline Pharmacy, you'll boost your competitive advantage like never before.

Enjoy the benefits of a near 50/50 split across front of shop and script sales¹ and increased visitation with Sister Club, Australia's biggest health and beauty loyalty program.

Plus the added peace of mind knowing we're in a prime position to successfully navigate any proposed industry changes.

* Priceline Pharmacy retail units sales data 1 Jul 2022 – 31 Dec 2022.

^ 2022 Priceline Pharmacy data.

¹ R12 FY23 as at May 2023 Priceline Pharmacy data.




a festival of *you*

Ready for success? Get in touch at JoinPricelinePharmacy@api.net.au

[Find out more](#)

Help relieve premenstrual symptoms and morning sickness with Pyridox.



Available from Symbion, Sigma API & CH2. Always read the label and follow the directions for use.

Today's issue of PD

Pharmacy Daily today features two pages of news, plus a front cover wrap from Priceline Pharmacy and full pages from:

- GS1
- PharmXchange

Gain advantage

PRICELINE has a 50/50 split across front-of-shop and script sales and is well prepared to navigate the upcoming industry changes.

To gain competitive advantage, and to learn more about partnering with Priceline Pharmacy, see the **cover page**.

Rely on GS1

GS1 can ensure that your records of medicine are captured accurately throughout the supply chain - to learn more, see **page three**.

PSA to deliver program

MENTAL health first aid training will be rolled out to at least 1,000 community pharmacists across South Australia.

Following a competitive procurement process by SA Health and the Office of the Chief Pharmacist, the Pharmaceutical Society of Australia (PSA) has been selected to deliver the specialised mental health training program.

The South Australian Government will invest \$350,000 over four years for the training as part of a \$2.65 million package of election commitments focused on improving and expanding support pharmacy, a statement said.

The training includes understanding the signs and symptoms of mental ill health, as well as learning practical skills to support people experiencing a mental health problem.

Pharmacists and pharmacy staff will also be educated on the types of help and support available and how to help people access



the support they need, including referring to other services.

The training will include the provision of information about developing mental health problems, including depression, anxiety and psychosis, as well as substance abuse.

SA Chief Pharmacist Naomi Burgess said, "as the selected training provider, Pharmaceutical Society of Australia will deliver training through its pharmacists who are accredited trainers in mental health first aid".

"The trainers will have shared experiences and understanding of the work environment which will be beneficial in how the face-to-face and online specialised program will be conducted."

Wound webinars

WOUNDS Australia has announced a number of free webinars set to take place during Wound Awareness Week from 04 to 10 Sep.

There will be six webinars in all with topics ranging from 'Caring for Wounds in Ageing Australians' to 'Wounds and Lifestyle Factors' and 'Getting Wound Care Right'.

On Fri 08 Sep there will be a trivia webinar focusing on fundamental wound care.

Wound Awareness Week has been set up to support the more than 450,000 Australians who are living with hard-to-heal wounds.

Currently wounds cost Australia's health and aged care budgets more than \$6 billion annually.

The webinars will take place at 12pm AEST every day with an additional one at 5pm on 07 Sep - interested professionals can register **HERE**.

DRAW THE LINE...

When it comes to Allergy relief



Affordable, quality healthcare supporting Australian families

Always read the label and follow the directions for use.

The APOTEX trademark is under license. Apotex Pty Ltd Macquarie Park NSW 2113. ABN 52 096 916 148. Copyright © CONSUMER-000779. June 2023. All rights reserved.

www.apohealth.com.au



Dispensary Corner

A WOMAN in the US reportedly lost a part of her finger to a drop box at a local public library.

Barbara Haverly, 62, said she was injured while attempting to return books last month, telling *The Washington Post* that “the whole thing is such a nightmare”.

What began as a quick errand turned into a bloody scene for Haverly at W.T. Bland Public Library, located on North Donnelly Street, she said.

Despite having returned books in the same manner many times before, Haverly reported feeling a rush of pain while pulling her left hand out of the box.

What she at first assumed was just uncomfortable hand placement turned out to be a severed middle finger, detached just below the fingernail.

Though she’s a registered nurse, Haverly told *The Post* that she didn’t know what to do while she watched herself bleed, claiming she was in shock.

As library staff rushed to her aid and called 911, one employee retrieved her severed finger from the drop-off receptacle, according to the writeup, however doctors could not reattach the appendage.

A sign has since been placed above the drop box reading: “Please do not place your hand inside this book drop”.

Christopher Largey, Haverly’s attorney, filed a claim against the city and told *The Post* it was unlike any other incident he’s seen in 20 years of practice.

“She didn’t do anything wrong other than return her books - to her peril,” Largey said.

Lilly’s first in class med

ELI Lilly Australia announced at the 2023 Australasian Diabetes Congress in Adelaide last week that Mounjaro (tirzepatide) will soon be made available in Australia for adults living with type 2 diabetes.

The registration and launch of Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade.

Mounjaro is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist.

It is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

It is to be used as monotherapy when metformin is not tolerated or in addition to other medicinal products for the treatment of type 2 diabetes.

The medicine is not recommended for the treatment of obesity or weight reduction for patients.

Mounjaro is the only registered single molecule for type 2 diabetes

that targets GIP and GLP-1 receptors.

These two hormones are involved in regulating blood glucose and account for 66% (44% GIP and 22% GLP-1) of glucose-dependent insulin release following a meal.

Tori Brown, Lilly General Manager of Australia, said, “when the Pharmaceutical Benefits Advisory Committee met in Jul this year they made the decision to not recommend the listing of Mounjaro (tirzepatide) on the PBS.

“Lilly is currently reviewing the details of the PBAC’s decision to determine the best path forward.

“Lilly has decided to launch Mounjaro as a private prescription so that Australian patients with type 2 diabetes can have access to the HbA1c and weight reductions that Mounjaro may offer.

“We are committed to making this first-in-class medicine accessible for adult patients living with type 2 diabetes and our ultimate goal is to secure reimbursement on the PBS,” Brown explained.

PSA tackles drug-induced deaths

THE Pharmaceutical Society of Australia (PSA) has made a plea to governments, health workers and support organisations to tackle the persistent challenge of deaths caused by intentional and unintentional drug overdose.

It comes after the release of Pennington Institute’s *Annual Overdose Report*, which found that there were 544 drug-induced unintentional deaths in Australia in 2021.

Other findings included the fact that two-thirds of all unintentional drug-induced deaths involved two or more drug types, and that 38% of the drugs involved in those deaths were anti-depressants.

PSA National President Dr Fei Sim urged the industry to “expand the way we assess risk” and have meaningful conversations with at-risk people.

“Some drug-drug combinations dramatically increase risk of unintentional drug-related death or hospitalisation, as this data tragically shows,” she said.

“Real Time Prescription Monitoring is now available and must be used...to have non-judgemental conversations with people about the potential risks associated with medicines, and particularly when multiple medicines are being used at the same time.”



Guild Update

New member resource page on 60-day

WHILE the Pharmacy Guild of Australia is continuing its campaign for a fairer outcome on 60-day dispensing, it has also launched a [new resource page](#) for members to address issues surrounding the policy’s implementation on the ground.

The policy will be in effect from this Friday 01 Sep with 92 medicines to be eligible for 60-day prescriptions.

The Guild’s new resources page on the implementation is available to members only and addresses issues such as:

- Charging for dispensing-related services;
- PBS frequently asked questions;
- And workforce planning.

The information contained on the page is general information and does not constitute pricing advice.

An individual pharmacist is responsible for determining the amount charged for the provision of PBS medicines and services and must ensure their pricing practices comply with applicable laws.

To access the resource, members can click **HERE**.

Members are also encouraged to regularly check the website and Guild social media for any further updates during Sep.



Can you **capture accurate records** of medicines at the point of care and throughout the supply chain?



Contact the **GS1 Healthcare team**

E healthcareteam@gs1au.org

W www.gs1au.org/for-your-industry/medicines

Experience Luxury: Win Two Business Class Flights to London!*



Enter for Your Chance to Win

Unlock incredible possibilities with PharmXchange! Enter now for your chance to win the ultimate reward: Flights for Two to London!

Win One of 3 Prizes:

1st Prize: Business Class Flights to London for 2 valued at \$25,000

2nd Prize: Travel or accommodation voucher valued at \$10,000

3rd Prize: Travel or accommodation voucher valued at \$5,000

How to Enter: Sign up for PharmXchange at pharmxchange.com.au – it's quick and easy. Register once for the competition in just one click. Place 6 orders on PharmXchange with a value of each invoice greater than \$600 ex GST anytime between July 31 - October 23, 2023. Multiple brands may be included in each order.

Who Can Enter? All registered PharmXchange pharmacies are eligible for entry. You could be one of the lucky winners to experience the thrill of flying in business class to London or utilise premium vouchers for luxury travel or accommodation. Join today, start ordering and enjoy the benefits!

Key partner: Travel & concierge services proudly provided by



[JOIN NOW TO ENTER](#)

*Find out more at:

www.pharmxchange.com.au for Terms & Conditions.